3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Completed
3
Terminated
2
Withdrawn
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
5
Other hematologic neoplasm
3
Other solid neoplasm
2
Other
2
Head & Neck
2
Gynecologic
2
CNS
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Conditions
Motor Activity
1
Lymphoma
1
Leukemia
1
Interventions
Cyclophosphamide
174
Rituximab
146
venetoclax
82
Specimen Handling
81
fludarabine
80
Vincristine
69
obinutuzumab
68
Prednisone
66
Doxorubicin
66
Biopsy
63
Magnetic Resonance Spectroscopy
62
Lenalidomide
54
zanubrutinib
52
Dexamethasone
48
Cytarabine
44
Methotrexate
43
blinatumomab
41
Immunotherapy, Adoptive
40
acalabrutinib
37
Bendamustine Hydrochloride
37
fludarabine phosphate
32
Etoposide
32
ibrutinib
30
polatuzumab vedotin
27
glofitamab
27
pirtobrutinib
25
orelabrutinib
25
Gemcitabine
24
Injections
21
Mercaptopurine
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Tablets
×
Lymphoid
×
Clear all
NCT06643221
2024-10-16
Allo-X
University of Arizona
Phase EARLY_PHASE1
Recruiting
100 enrolled